CO5271717A1 - Combinaciones farmaceuticas - Google Patents

Combinaciones farmaceuticas

Info

Publication number
CO5271717A1
CO5271717A1 CO00091389A CO00091389A CO5271717A1 CO 5271717 A1 CO5271717 A1 CO 5271717A1 CO 00091389 A CO00091389 A CO 00091389A CO 00091389 A CO00091389 A CO 00091389A CO 5271717 A1 CO5271717 A1 CO 5271717A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical combinations
components
pharmaceutically acceptable
component
acceptable derivative
Prior art date
Application number
CO00091389A
Other languages
English (en)
Inventor
John Dixon
Robert Humphries
Gavin Jarvis
Ian Kirk
Original Assignee
Astrazenaca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazenaca Ab filed Critical Astrazenaca Ab
Publication of CO5271717A1 publication Critical patent/CO5271717A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un kit de partes que comprende:Un antagonista de los receptores P2T o un derivado farmacéuticamente aceptable de éste (componente a); yOtro agente anti-trombótico o un derivado farmacéuticamente aceptable de éste (componente b);en donde los componentes (a) y (b) se suministran cada uno en una forma (que puede ser la misma o diferente) la cual es apropiada para la administración combinada de los componentes.<EMI FILE="00091389_1" ID="1" IMF=JPEG >
CO00091389A 1999-12-01 2000-11-29 Combinaciones farmaceuticas CO5271717A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
CO5271717A1 true CO5271717A1 (es) 2003-04-30

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00091389A CO5271717A1 (es) 1999-12-01 2000-11-29 Combinaciones farmaceuticas

Country Status (33)

Country Link
US (2) US20030032618A1 (es)
EP (2) EP1719526A3 (es)
JP (1) JP2003515565A (es)
KR (1) KR100785953B1 (es)
CN (1) CN1402639A (es)
AR (1) AR033658A1 (es)
AT (1) ATE332698T1 (es)
AU (1) AU781691B2 (es)
BR (1) BR0016043A (es)
CA (1) CA2391161C (es)
CO (1) CO5271717A1 (es)
CY (1) CY1105211T1 (es)
CZ (1) CZ300925B6 (es)
DE (1) DE60029340T2 (es)
DK (1) DK1237559T3 (es)
EE (1) EE05127B1 (es)
ES (1) ES2267591T3 (es)
HK (1) HK1047893A1 (es)
HU (1) HU230890B1 (es)
IL (1) IL149495A0 (es)
IS (1) IS2841B (es)
MX (1) MXPA02004871A (es)
MY (1) MY128896A (es)
NO (1) NO331215B1 (es)
NZ (2) NZ518904A (es)
PT (1) PT1237559E (es)
RU (1) RU2242232C2 (es)
SE (1) SE9904377D0 (es)
SI (1) SI1237559T1 (es)
SK (1) SK288707B6 (es)
TW (1) TWI251491B (es)
WO (1) WO2001039781A1 (es)
ZA (1) ZA200203707B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
AU2006292946B2 (en) * 2005-09-21 2009-12-10 Chong Kun Dang Pharmaceutical Corp. Novel resinate complex of s-clopidogrel and production method thereof
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2778880C (en) 2009-11-11 2018-02-13 The Medicines Company Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
AU2013381855B2 (en) 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
MX2019015448A (es) 2017-06-23 2020-02-19 Chiesi Farm Spa Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
HUT64967A (en) * 1991-04-06 1994-03-28 Fisons Plc Atp analogues and pharmaceutical compositions containing them
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharma Prod N-alkyl-2-substituierte atp-analoge
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
BR9609467A (pt) * 1995-07-11 1999-03-02 Astra Pharma Prod Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
WO2004031143A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US20060160887A1 (en) * 2003-07-16 2006-07-20 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
DK1237559T3 (da) 2006-10-30
IL149495A0 (en) 2004-03-28
DE60029340T2 (de) 2007-07-19
ZA200203707B (en) 2003-10-29
HUP0203585A3 (en) 2005-01-28
TWI251491B (en) 2006-03-21
IS2841B (is) 2013-08-15
NZ518904A (en) 2004-02-27
CY1105211T1 (el) 2010-03-03
EP1237559B1 (en) 2006-07-12
KR20020069201A (ko) 2002-08-29
PL355841A1 (en) 2004-05-17
EE200200271A (et) 2003-06-16
NO20022606L (no) 2002-07-11
CA2391161A1 (en) 2001-06-07
NZ530058A (en) 2005-04-29
EP1719526A2 (en) 2006-11-08
ES2267591T3 (es) 2007-03-16
NO331215B1 (no) 2011-11-07
HK1047893A1 (en) 2003-03-14
KR100785953B1 (ko) 2007-12-14
CZ20021887A3 (cs) 2002-11-13
IS6398A (is) 2002-05-27
SE9904377D0 (sv) 1999-12-01
DE60029340D1 (de) 2006-08-24
SK7502002A3 (en) 2003-02-04
HUP0203585A2 (hu) 2003-03-28
NO20022606D0 (no) 2002-05-31
RU2002117296A (ru) 2004-01-20
PT1237559E (pt) 2006-10-31
AU1910901A (en) 2001-06-12
MY128896A (en) 2007-02-28
CA2391161C (en) 2010-10-05
US20030032618A1 (en) 2003-02-13
US20060270607A1 (en) 2006-11-30
AR033658A1 (es) 2004-01-07
WO2001039781A1 (en) 2001-06-07
ATE332698T1 (de) 2006-08-15
RU2242232C2 (ru) 2004-12-20
SI1237559T1 (sl) 2007-02-28
SK288707B6 (sk) 2019-10-02
AU781691B2 (en) 2005-06-09
EE05127B1 (et) 2009-02-16
BR0016043A (pt) 2002-07-23
EP1237559A1 (en) 2002-09-11
JP2003515565A (ja) 2003-05-07
CZ300925B6 (cs) 2009-09-09
MXPA02004871A (es) 2002-08-30
CN1402639A (zh) 2003-03-12
HU230890B1 (hu) 2018-12-28
EP1719526A3 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
CO5271717A1 (es) Combinaciones farmaceuticas
DK1414451T3 (da) Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
CO5251429A1 (es) Derivados de ter-butil-(7-metil-imidazo(1,2-a)piridin-3- il)-amina procedimiento para su preparacion, medicamentos que los contienen, su uso para la preparacion de un medicamento para la inhibicion de la no-sintasa y composiciones farmaceuticas que l
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ATE215081T1 (de) Gonadotropin releasing hormon- antagonisten
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
UY26817A1 (es) Agentes antiinflamatorios selectivos de glucocorticoides
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
EP1337249A4 (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
EE05123B1 (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
CO5210886A1 (es) Aplicacion de compuestos de imidazolidin-2, 4-diona susti- tuida como antalgicos
ES2147309T3 (es) Composiciones de ondansetron liofilizadas.
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
BRPI0413028A (pt) composto, uso de um composto, composição farmacêutica, e, kit farmacêutico
AR005238A1 (es) Dihidropirimidinas y usos de las mismas, composicion farmaceutica.
DK1404331T3 (da) Sustained release-formuleringer af oxymorphon
CO5160329A1 (es) Metodo para proveer absorcion incrementada de una amina far- maceuticamente aceptable en la sangre de un humano y composi cion que comprende una amina farmaceuticamente un farmaco antiinflamatorio no esteroidal

Legal Events

Date Code Title Description
FC Application refused